I wrote: I'm not expecting another chance to buy at 40c
Looks like I might get that chance after all, the way the share price is trending! The trauma KV is going through is bad news for Acrux: I don't think it will affect Evamist, but it's likely to constrain the resources available for the development of all those other products.
Acrux still looks like one of the safer biotech companies, but with the sector getting a pounding there's now a plethora of attractive choices for biotech investors.
Add to My Watchlist
What is My Watchlist?
